12 patients won't be enough to approve MPL for global use but it should be enough to gain the orphan drug designation.
If companies have less than 2 quarters of funding they just need to answer a few extra questions in their quarterly report. I've held a few companies that have done this without consequence.
12 patients won't be enough to approve MPL for global use but it...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $73.24M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.5¢ | 17.5¢ | $68.67K | 382.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 203260 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 57357 | 5 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.0¢ |
Change
0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 17.8¢ | 18.0¢ | 17.5¢ | 253129 | ||
| Last updated 15.56pm 27/05/2024 ? | |||||
| PAA (ASX) Chart |